Cognitive behavioral therapy may improve a diverse array of depressive symptoms in patients with Parkinson disease.
Subjectively-identified impairments in quality of life is the most important predictor of benefit from deep brain stimulation in Parkinson disease with early motor complications.
Inbrija, the first inhaled levodopa, has been made available by Acorda Therapeutics for the intermittent treatment of OFF episodes in patients with Parkinson disease treated with carbidopa/levodopa.
Investigators evaluated the relationship of gout with the risk for incident Parkinson disease in adults ≥age 65.
The pooled analysis, which compared 28 different outcome measures of single-task and dual-task gait speed, found a moderate to large standardized mean difference effect.
Researchers assessed microstructural characteristics of the corpus callosum with diffusion tensor imaging and evaluated their association with cognitive impairment in Parkinson disease.
Of the 18 patients with recurrent dystonic symptoms, 7 of the 9 who underwent repeat ventro-oral thalamotomy achieved improvement.Of the 18 patients with recurrent dystonic symptoms, 7 of the 9 who underwent repeat ventro-oral thalamotomy achieved improvement.
Some sleep-related movement disorders are well known, like restless legs syndrome, but less common sleep-related movement disorders are often overlooked.
The most frequently reported symptoms while patients waited for ON-period included slowness, fatigue, reduced dexterity, difficulty in walking, and problems with balance.
Deep brain stimulation of the internal globus pallidus is associated with improved quality of life and is possibly effective for reducing symptoms of dystonia in X-linked dystonia parkinsonism.